Stoke Therapeutics (STOK) CFO exercises 14,750 RSUs, now holding 14,750 shares

Rhea-AI Filing Summary

Stoke Therapeutics Chief Financial Officer Thomas Leggett exercised restricted stock units into common shares in a routine compensation-related transaction. On March 15, 2026, he exercised 14,750 restricted stock units, receiving 14,750 shares of common stock at an exercise price of $0.00 per share.

After the transaction, Leggett directly holds 14,750 shares of common stock and 44,250 restricted stock units. Each RSU represents the right to receive one share of common stock upon settlement, and the award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service with the company.

Insights

Equity compensation and governance analyst

CFO exercised 14,750 RSUs into shares and retained the stock, a routine equity compensation event.

The filing shows Thomas Leggett, Chief Financial Officer of Stoke Therapeutics, exercising 14,750 restricted stock units into the same number of common shares at an exercise price of $0.00. This is coded as an option or derivative exercise (transaction code M), not an open-market purchase or sale.

Following the transaction, he directly holds 14,750 common shares and 44,250 remaining restricted stock units. The RSU award vests in four equal annual installments starting on March 15, 2026, conditioned on continued service. With no accompanying sales or tax-withholding dispositions reported, this appears to be an exercise-and-hold pattern typical of executive equity vesting rather than a signal-driven market trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leggett Thomas

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		14,750	A	$0	14,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/15/2026		M			14,750	(2)	03/15/2029	Common Stock	14,750	$0	44,250	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

2. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Stoke Therapeutics (STOK) report for CFO Thomas Leggett?

Stoke Therapeutics reported that CFO Thomas Leggett exercised 14,750 restricted stock units, receiving 14,750 shares of common stock. The exercise price was $0.00 per share, reflecting a standard equity compensation vesting event rather than an open-market purchase.

How many Stoke Therapeutics (STOK) shares does the CFO hold after this Form 4 transaction?

After the transaction, CFO Thomas Leggett directly holds 14,750 shares of common stock. He also holds 44,250 restricted stock units, each representing a contingent right to receive one share of Stoke Therapeutics common stock upon settlement, according to the filing.

What do the restricted stock units in the Stoke Therapeutics (STOK) Form 4 represent?

Each restricted stock unit, or RSU, represents a contingent right to receive one share of Stoke Therapeutics common stock upon settlement. When RSUs vest and are settled, the holder receives the corresponding number of shares without paying an exercise price, as disclosed.

How does the RSU vesting schedule work for the Stoke Therapeutics (STOK) CFO award?

The RSU award vests as to one-quarter of the total award each year, starting on March 15, 2026. Vesting is subject to the CFO’s continued service with Stoke Therapeutics through each annual vesting date, as stated in the footnotes.

Was there any open-market buying or selling in this Stoke Therapeutics (STOK) Form 4?

No open-market buying or selling is reported. The Form 4 shows a derivative exercise (code M) where RSUs converted into 14,750 common shares at $0.00 per share, without any accompanying sales or tax-withholding dispositions.